GVK BIO announces the appointment of Axel Schleyer, Ph.D. as Chief Executive Officer, Aragen Bioscience, Inc.

May 08, 2019, Hyderabad, India/California, US: GVK BIO is pleased to announce the appointment of  Dr. Axel Schleyer as Chief Executive Officer, Aragen Bioscience Inc.  

“I am delighted to welcome Dr. Axel Schleyer as the Chief Executive Officer, Aragen Bioscience. Axel brings a wealth of business, technology, regulatory and strategic acumen, and has an impressive record of consistently delivering high performance with a customer focus, said Manni Kantipudi, Chairman, Aragen Bioscience, Director & CEO, GVK BIO. “We are confident that under his leadership, Aragen will expand its offering, and build on its growth over the past few years”.

“I am excited to lead Aragen Bioscience and look forward to assisting our customers in developing solutions that impact human health. With large molecules contributing to approximately 40% of the global portfolio, interest in Biologics research continues to grow rapidly” added Dr. Axel Schleyer. “With its strong scientific leadership, ‘customer first’ culture, state-of-the-art infrastructure, and an ideal location in the Bay area, Aragen is well positioned to benefit from market trends.

A seasoned Pharmaceutical and Biotechnology professional, Dr. Schleyer has over two decades of industry experience, building and leading high-performance teams, spearheading global business initiatives, and formulating business strategies resulting in successful outcomes. Prior to joining Aragen, Dr. Schleyer served as Senior Vice President, AGC Biologics and has held roles of increasing responsibilities at Lonza, Siegfried, Baxter Healthcare and Boehringer Ingelheim.

Dr. Schleyer has completed his postdoctoral studies at The Scripps Research Institute, La Jolla, CA and at Carlsberg Institute, Copenhagen, Denmark. He completed his Ph.D. in Chemistry from the University of Hamburg, and holds a Master of Business Administration degree from California State University, San Marcos.